Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay

This story has been updated to correct the type of biomarker used in MDxHealth's SelectMDx assay.

NEW YORK (GenomeWeb) – Belgian diagnostic firm MDxHealth announced today that it has signed a distribution agreement with LifeLabs to offer MDxHealth's SelectMDx assay in Canada.

Toronto-based LifeLabs will serve as the exclusive distributor in Canada for the noninvasive liquid biopsy assay, which is a urine-based assay that measures the expression of two mRNA cancer-related biomarkers to stratify patients who have signs of aggressive prostate cancer.

Researchers will test liquid biopsy samples in MDxHealth's clinical diagnostic laboratory in Irvine, California, while LifeLabs will reimburse MDxHealth for all testing services performed at the lab.

"By making this innovative, noninvasive test available, we are improving the quality of prostate cancer diagnosis and delivering healthier outcomes for Canadians," LifeLabs CEO Charles Brown said in a statement.

Financial details of the agreement were not disclosed.

"With over 25,000 US patients tested with SelectMDx to date, the test is clearly gaining momentum to become the standard of care in diagnosing patients with increased risk for aggressive prostate cancer," MDxHealth CEO Jan Groen said in a statement. "This partnership agreement with LifeLabs demonstrates our commitment to making SelectMDx widely available in North America and to offering a valuable and accurate alternative for patients at risk for prostate cancer."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more